SELECT NEOADJUVANT DOSING AND ADMINISTRATION
Assessment of HER2 protein overexpression and HER2 gene amplification should be performed using FDA-approved tests specific for breast cancer by laboratories with demonstrated proficiency.1
To begin PERJETA and Herceptin® (trastuzumab)-based therapy in the neoadjuvant setting, patients must have HER2+ breast cancer with locally advanced, inflammatory, or early stage breast cancer (either node-positive or tumor size >2 cm).1
Please see the full Prescribing Information for complete dosing and administration, including dose considerations, dose modifications, preparation, storage, and handling. You can also download the PERJETA Dosing & Administration Guide.